Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability,safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol,separately and in combination

Abstract

Rationale

The pathophysiology of most lacunar stroke, a form of small vessel disease, is thought to differ from large artery atherothrombo- or cardio-embolic stroke. Licensed drugs, isosorbide mononitrate and cilostazol, have promising mechanisms of action to support their testing to prevent stroke recurrence, cognitive impairment, or radiological progression after lacunar stroke.

Aim

LACI-1 will assess the tolerability, safety, and efficacy, by dose, of isosorbide mononitrate and cilostazol, alone and in combination, in patients with ischemic lacunar stroke.

Sample size

A sample of 60 provides 80+% power (significance 0.05) to detect a difference of 35% (90% versus 55%) between those reaching target dose on one versus both drugs.

Methods and design

LACI-1 is a phase IIa partial factorial, dose-escalation, prospective, randomized, open label, blinded endpoint trial. Participants are randomized to isosorbide mononitrate and/or cilostazol for 11 weeks with dose escalation to target as tolerated in two centers (Edinburgh, Nottingham). At three visits, tolerability, safety, blood pressure, pulse wave velocity, and platelet function are assessed, plus magnetic resonance imaging to assess cerebrovascular reactivity in a subgroup.

Study outcomes

Primary: proportion of patients completing study achieving target maximum dose.

Secondary

symptoms whilst taking medications; safety (hemorrhage, recurrent vascular events, falls); blood pressure, platelet function, arterial stiffness, and cerebrovascular reactivity.

Discussion

This study will inform the design of a larger phase III trial of isosorbide mononitrate and cilostazol in lacunar stroke, whilst providing data on the drugs’ effects on vascular and platelet function.

Trial registration

ISRCTN (ISRCTN12580546) and EudraCT (2015-001953-33).

Keywords

Lacunar stroke small vessel disease cilostazol isosorbide mononitrate endothelium blood–brain barrier white matter hyperintensities cerebrovascular reactivity

Get full access to this article

View all access options for this article.

References

Wardlaw

Smith

Dichgans

. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013; 12: 483–497.

Debette

Markus

. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. Br Med J 2010; 341: c3666.

Wiseman

Marlborough

Doubal

Webb

Wardlaw

. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis 2014; 37: 64–75.

Stevenson

Doubal

Shuler

Wardlaw

. A systematic review of dynamic cerebral and peripheral endothelial function in lacunar stroke versus controls. Stroke 2010; 41: e434–e42.

Bailey

Smith

Sudlow

CLM

Wardlaw

. Pathology of lacunar ischaemic stroke in humans – a systematic review. Brain Pathol 2012; 22: 583–591.

Wardlaw

Makin

Hernández

MCV

et al.

Blood–brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimer's Dementia 2017; 13: 634–643.

Blair

Doubal

Thrippleton

Marshall

Wardlaw

. Magnetic resonance imaging for assessment of cerebrovascular reactivity in cerebral small vessel disease. A systematic review. J Cereb Blood Flow Metab 2016; 36: 833–841.

Bath

Wardlaw

. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke 2015; 10: 469–478.

Rashid

Whitehurst

Lawson

Bath

. Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcome. J Stroke Cerebrovasc Dis 2003; 12: 82–87.

10.

Ferlito

Gallina

Pitari

Bianchi

. Nitric oxide plasma levels in patients with chronic and acute cerebrovascular disorders. Panminerva Med 1998; 40: 51–54.

11.

Hassan

Hunt

O'Sullivan

et al.

Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003; 126: 424–432.

12.

Woodhouse

Scutt

Krishnan

et al.

Effect of hyperacute administration (within 6 hours) of transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after stroke: subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial. Stroke 2015; 46: 3194–3201.

13.

Jackson

Hutchison

Dennis

et al.

Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy?

Stroke 2010; 41: 624–629.

14.

Bedenis

Stewart

Cleanthis

et al.

Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014. Issue 10. Art. No.: CD003748. DOI: 10.1002/14651858.CD003748.pub4.

15.

Miyamoto

Pham

L-DD

Hayakawa

et al.

Age-related decline in oligodendrogenesis retards white matter repair in mice. Stroke 2013; 44: 2573–2578.

16.

Omote

Deguchi

Tian

et al.

Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol. Stroke 2012; 43: 1639–1646.

17.

Han

Lee

Kim

et al.

Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. Eur Neurol 2012; 69: 33–40.

18.

Uchiyama

Demaerschalk

Goto

et al.

Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18: 482–490.

19.

Kamal

Naqvi

Husain

Khealani

. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011. (1): CD008076.

20.

DiNicolantonio

Lavie

Fares

et al.

Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013; 112: 1230–1234.

21.

Shi

Malaguit

Zhang

Chen

. The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis. BMC Neurol 2014; 14: 1–10.

22.

Klarenbeek

van Oostenbrugge

Rouhl

Knottnerus

Staals

. Ambulatory blood pressure in patients with lacunar stroke: association with total MRI burden of cerebral small vessel disease. Stroke 2013; 44: 2995–2999.

23.

Fox

May

Shah

Neubert

Heptinstall

. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009; 20: 250–259.

24.

Wardlaw

Smith

Biessels

et al.

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration: a united approach. Lancet Neurol 2013; 12: 822–838.

25.

Valdés Hernández

Armitage

Thrippleton

et al.

Rationale, design and methodology of the image analysis protocol for studies of patients with cerebral small vessel disease and mild stroke. Brain Behav 2015. DOI: 10.1002/brb3.415.

26.

Hansson

Hedner

Dahlöf

. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Pressure 1992; 1: 113–119.

27.

Nishiyama

Seyama

Okano

et al.

Escalation regimen of cilostazol for acute brain infarction. Internal Med 2011; 50: 1559–1563.

28.

de Vos-Koppelaar

Kerkhoff

de Vogel

Zock

Dieleman

. The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). Cerebrovasc Dis 2014; 37: 285–289.

29.

Schmidt

Scheltens

Erkinjuntti

et al.

White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004; 63: 139–144.

30.

Sprigg

Gray

England

et al.

A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS ONE 2008; 3: e2852.

31.

Nakamura

Tsuruta

Uchiyama

. Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci 2012; 313: 22–26.

32.

Lee

Bae

Kang

et al.

Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011; 32: 65–71.

33.

Shinohara

Katayama

Uchiyama

et al.

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959–968.

34.

Shimizu

Tominaga

Ogawa

et al.

Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. J Stroke Cerebrovasc Dis 2013; 22: 449–456.

35.

Gotoh

Tohgi

Hirai

et al.

Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147–157.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.53 MB